Kornimate/medical-research-clean huggingface dataset:
the significance of arrhythmias in athletes

Conditions: Sudden Death

Summary: athletes with complex ventricular arrhythmias are potentially at risk of sudden death. the aim of the study is to investigate the relevance of ventricular tachyarrhythmias induced by an exercise test in a retrospectively evaluated athletic population.

athletes with complex ventricular arrhythmias are potentially at risk of sudden death. the risk is increased when the athletes are engaged in competitive activities. ventricular premature beats (vpb's) are a common finding in the athletic heart. in the majority of cases these arrhythmias are part of the "athlete's heart syndrome" and do not increase the risk of sudden death in the athletes with an apparently normal heart. the data available in the literature deal with ventricular arrhythmias assessed only by 24-h ambulatory electrocardiograms. to date, there are no guidelines concerning athletes who develop ventricular arrhythmias during a stress test. it is unclear whether they should be allowed to continue with their competitive activity or they should be denied to do so. a study looking at the long term follow-up of these athletes will help us determine whether the development of ventricular arrhythmia during a stress test imposes any risk on the athletes.

Eligibility criteria:
inclusion criteria: * competitive athletes less than 35 yo * competitive athletes with ventricular arrhythmias on baseline or recovery in a stress test * competitive athletes with ventricular arrhythmia during exercise exclusion criteria: * athletes who don't meet the exclusion criteria.

Keywords: arrhythmias athletes exercise
investigating markers of energy metabolism in pregnant women with insulin resistance

Conditions: Gestational Diabetes; Type 2 Diabetes Mellitus

Summary: the investigators seek to examine the metabolic changes that occur amongst obese and lean pregnant women with normal glycemic control as well as pregnant women with diabetes mellitus (gestational diabetes and pre-existing type 2 diabetes mellitus) compared to non-pregnant age matched controls. given the adaptive tendency of the maternal body to use alternative energy sources such as ketones and free fatty acids rather than glucose and to shunt glucose and amino acids to the fetus, the investigators hypothesize that the amino acid and fatty acid profile will be reflective of this adaptive change and that maternal insulin resistance will result in alterations in this pattern in both the plasma and csf. furthermore, the investigators also hypothesize that maternal degrees of insulin resistance will also be reflected in csf hormonal changes.

we seek to investigate for the first time whether csf branched chain amino acid, free fatty acid, and energy regulatory hormone levels are altered in comparison to plasma levels among pregnant and non-pregnant individuals with varying degrees of insulin resistance. furthermore, we seek to understand the effects of pregnancy on central and peripheral energy metabolism using metabolomic profiling as well as traditional hormonal measurements in maternal blood, urine, cerebrospinal fluid as well as cord blood.

Eligibility criteria:
inclusion criteria: * pregnant women ages 18-45, pre-pregnancy bmi 18-30 with normal glycemic control scheduled for an elective cesarean delivery at yale-new haven hospital on the labor and birth unit * pregnant women ages 18-45, pre-pregnancy bmi \>30 with normal glycemic control scheduled for an elective cesarean delivery at yale-new haven hospital on the labor and birth unit * pregnant women ages 18-45 with diabetes (gestational or pre-existing type 2 dm) scheduled for an elective cesarean delivery at yale-new haven hospital on the labor and birth unit * non-pregnant, non-diabetic women age 18-45 scheduled for lumbar puncture at the yale-new haven hospital lumbar puncture clinic * able to read and understand english at 6th grade level or higher exclusion criteria: * medical disorders other than diabetes. including psychiatric disorders, alcohol abuse, hiv, hepatitis, renal, hepatic disease, heart disease, active systemic infection, malignancy * pregnancy related medical problems including preeclampsia * major congenital fetal anomalies * smoking and illicit drugs (marijuana, cocaine, benzodiazepines, barbituates) * use of weight loss supplements or dieting 6 months prior to study. * corticosteroid use within 6 months of study. * uncontrolled thyroid disease * medications other than multivitamin, folic acid, or diabetic medications.

Keywords: insulin metabolomics
sedation of morbidly obese for balloon insertion

Conditions: Morbid Obesity

Summary: this prospective study will assess the value of different supplements to orpofol bases anesthesia in morbidly obes e patients scheduled for balloon insertion. two common drugs will be added to propofol bases anesthesia;ketamine or fentanyl. effect on prpofol consumption, post-procedure recovery profile, and patient satisfaction will be the study objectives.


Eligibility criteria:
inclusion criteria: * morbid obese indicated for gastric balloon insertion exclusion criteria: - refusal hypersensitivity to any of the study drugs
efficacy of magnesium sulfate bolus in pediatric patients with bronchiolitis

Conditions: Bronchiolitis, Viral

Summary: the purpose of this study is to more rigorously evaluate the response to a single bolus of magnesium sulfate in a population of patients with moderate to severe bronchiolitis. the primary outcome will be to evaluate the effect of this therapy on clinical respiratory status. secondary outcomes of interest will include the incidence of adverse effects and safety profile of magnesium bolus use in this population.

this randomized placebo-controlled pilot study is designed to evaluate the above referenced outcomes. study drug initiation will occur in the local pediatric intensive care unit in patients with a clinical diagnosis of bronchiolitis and whose parent/lar consents for their participation. our goal is to enroll and evaluate a total of 40 patients. upon obtaining informed consent, the participant will receive an enrollment history and physical to include: baseline modified pulmonary index score (mpis), blood pressure, vital signs, and epidemiologic data. the participant will then receive either a bolus of 50mg/kg magnesium sulfate (mgso4) or normal saline as placebo medication over twenty minutes. vital signs and mpis will be monitored according to the study schedule, for a total of six hours. during the period of monitoring subjects will not receive additional bronchodilators unless otherwise deemed clinically necessary by the subject's attending physician. if administered, these will be recorded by investigative team.

Eligibility criteria:
inclusion criteria: * infants under 12 months of age * admitted to the pediatric intensive care unit * moderate/severe bronchiolitis using mpis * less than 24 hours of admission to the picu * parent/lar consents for infant to participate exclusion criteria: * patients with the following conditions are ineligible: chronic lung disease, unrepaired congenital heart disease, and cyanotic heart disease.
assessment of the prevalence of major psychiatric disorders in a cohort of women with clinical criteria corresponding to pure, abortive-form, obstetrical, antiphospholipid syndrome

Conditions: Antiphospholipid Syndrome; Factor V Leiden Thrombophilia

Summary: the primary objective of this study was to evaluate and compare the prevalence of the following psychiatric pathologies (based on the mini5.0.0 questionnaire) among 3 groups of women (leiden versus ap1ab-positive versus thrombophilia-negative) with similar obstetrical histories 10 years after their initial assessment/diagnosis. * mood disorders, including depressive episodes during the previous two weeks, recurrent depressive disorders at any point in life, dysthymia in the last two years, or any current or past manic episode; * anxiety disorders, including current agoraphobia, current panic disorders, agoraphobia with panic disorders, current social phobia, generalized anxiety in the last 6 months, or current posttraumatic stress syndrome; * apparent psychotic syndromes, including isolated or recurrent psychotic syndromes, past or present (clinically validated), * current alcohol or drug problems (dependence or abuse).


Eligibility criteria:
inclusion criteria: * three unexplained consecutive spontaneous abortions before the 10th week of gestation (the recurrent embryo loss subgroup) - or - * one unexplained death of a morphologically normal fetus (fetal loss) at or after the 10th week of gestation (fetal loss subgroup). exclusion criteria: * any history of thrombotic events or any treatment given during previous pregnancies that might have modified the natural course of the condition * women whose pregnancy losses could be explained by infectious, metabolic, anatomic or hormonal facotrs, or associated with paternal or maternal chromosomal causes * seropositivity for hiv, hepatitis b or c * women with antithrombin, protein c, or protein s deficiency, and women with abnormal fibrinogen or with the jak2 v617f mutation were further excluded.
impact of beans and oats snack bar on hypertriglyceridemic women

Conditions: Hypertriglyceridemia; Obesity

Summary: hypertriglyceridemia is a serious condition in the mexican population and it is considered a major risk factor for cardiovascular disease. current efforts to prevent dyslipidemia and lipids alteration include the development of functional products as an alternative for the management of hypertriglyceridemia. common beans (phaseolus vulgaris l.) are a recognized good source of bioactive compounds, mainly phenolic compounds, total dietary fiber (insoluble and soluble fiber, resistant starch and oligosaccharides), saponins, and phytosterols that exert hypolipidemic effects. in this sense, the development of beans-based food products is an alternative for improving the general health status. in previous work, a beans-oats snack bar formulation was found to be a promising potential functional product. in order to validate those results, the aim of this works was to assess a clinical trial was conducted with mexican women to assess the effect of daily consumption of the functional product on serum triglycerides and certain plasma proteins involved in lipids metabolism in a clinical trial. the clinical trial was 2 months, randomized parallel study where 32 women with elevated triglycerides were randomized into the treatment group and control group. the control group received nutritional orientation whereas the treatment group received the orientation and consumed 50 g of the product per day. fasting blood samples were collected at baseline and the end of the study, obtaining serum and plasma for analysis of lipids profile, glucose, and biomarkers. to determine changes in plasma proteins, a 182 protein human obesity antibody array was used, and the results were analyzed using a bioinformatic-based analysis from ingenuity pathways analysis (qiagen)


Eligibility criteria:
inclusion criteria: * no current diagnoses of illnesses. * triglycerides levels among 150 and 350 mg/dl. * no allergies to common beans and oats. * not pregnant or lactating. exclusion criteria: * if they had current diagnoses of diabetes, hypertension, irritable bowel syndrome, or cancer. * taking anti-inflammatory drugs. * fasting glucose \>100 mg/dl, total cholesterol \>240 mg/dl, ldl c\>160 mg/dl. * reported intolerances to bosb ingredients.

Keywords: common beans oats proteomic analysis phenolic compounds dietary fiber
adult influenza vaccination text message reminders with electronic health record alerts

Conditions: Influenza

Summary: influenza infection leads to on average 3000-49,0000 deaths and 150,000 hospitalizations annually. while vaccination is the cornerstone of preventing influenza infection, vaccination coverage in adults is low. latino adults have the lowest coverage rates. text message reminders have been used successfully for improving influenza vaccination for children. this study will assess the use of text messaging to improve influenza vaccination coverage rates in a largely minority, publicly insured adult population. we will also assess if the patient having received a text message makes the patient more likely to accept vaccination when their provider has received in electronic alert regarding need for influenza vaccination in the electronic health record.


Eligibility criteria:
inclusion criteria: * \> or = 18 years of age * at least one visit to the aim clinic during previous 6 months * a cell phone number in the registration system * fluent in english or spanish exclusion criteria: - receipt of influenza vaccination during the 2014-2015 influenza season prior to randomization
use of a rapid test for gonorrhea & chlamydia for women presenting with possible sexually transmitted infections

Conditions: Sexually Transmitted Infection; Gonorrhea Female; Chlamydia Females

Summary: the purpose of this study is to evaluate the effect of utilizing a rapid turnaround ct/ng test on treatment of female patients in the emergency department or urgent care setting with possible stis.

all females ages 18-55 presenting to the university of maryland medical center emergency department or urgent care whose provider suspects sexually transmitted infection will be offered study enrollment and be randomly assigned to either the control or the experimental group. both groups will have a urinalysis, a pregnancy test, a pelvic exam, and an endocervical sample collected, but the experimental group's urine will be used to run the rapid turnaround test (rtat) instead of the standard pcr. data will be collected regarding provider decision making, length of stay in the emergency department, patient satisfaction, clinician satisfaction, further healthcare sought by patient, and cost surrounding each treatment.

Eligibility criteria:
inclusion criteria: * female patients age 18-55 * signs or symptoms consistent with sexually transmitted infection * medical provider willing to consider the result of the rapid turnaround test in decision to treat for gonorrhea/chlamydia * must have a urine specimen obtained and a pelvic exam performed as part of the anticipated standard of care evaluation * provides informed consent exclusion criteria: * signs of systemic infection * patient in whom the provider is unwilling to consider the result of the rapid turnaround test * patient who reports being treated for either gonorrhea or chlamydia in the preceding 3 months * patients undergoing evaluation for sexual assault * patients that are known to be pregnant or express concern that they may be pregnant * incarcerated patients * students/employees of the facility * presence of any other condition(s) that the investigator feels makes the patient unsuitable for study inclusion.

Keywords: rapid turnaround test rtat gonorrhea chlamydia sti
tolerability and safety study of fluval p monovalent influenza vaccine in children

Conditions: Influenza

Summary: to determine the tolerability and safety of fluval p monovalent influenza vaccine in children.

this is an open, uncontrolled study to assess safety and tolerability of fluval p monovalent influenza vaccine (whole virus, inactivated, adjuvanted with alumn phosphate gel) containing 6 mcgha per 0.5ml active ingredient in children of 6-36 months of age. the vaccination is not repeated. tolerability and safety (incidence of adverse events) of the study drug is assessed after day 28 then after day 180-210 following the vaccination.

Eligibility criteria:
inclusion criteria: * children aged 6 to 36 months, both sexes; * are in good health (as determined by vital signs and existing medical condition) or are in stable medical condition. subjects will not be excluded with known adequately treated clinically significant organ or systemic diseases (e.g. asthma or diabetes), such that, in the opinion of the investigator, the significance of the disease will not compromise the subject's participation in the study; * capability of the legitimate representative of the volunteer to understand and comply with planned study procedures; * legitimate representative of the volunteer provide written informed consent prior to initiation of study procedures; * absence of existence of any exclusion criteria. exclusion criteria: * known allergy to eggs or other components of the vaccine (in particular mercury); * history of guillain-barré syndrome; * active neoplasm; * former or on-going immunosuppressive therapy; * concomitant corticosteroid therapy, including high-dose inhaled corticosteroids; * immunoglobulin (or similar blood product) therapy within 3 months prior to vaccination; * documented hiv, hbv or hcv infection; * chronic illness that, in the opinion of the investigator, may have effect on the participation in the study; * acute febrile respiratory illness within one week prior to vaccination; * vaccine therapy within 4 weeks prior to vaccination; * influenza vaccination within 6 months prior to vaccination; * experimental drug therapy within 1 month prior to vaccination; * past or current psychiatric disease of the legitimate representative that upon judgement of the investigator may have effect on the objective decision-making of the legitimate representative; * alcohol or drug abuse of the legitimate representative.

Keywords: influenza pandemic vaccine seasonal vaccine prevention influenza vaccine influenza in humans pandemic influenza in humans influenza vaccine for children
irbesartan/hydrochlorothiazide (hctz) combination therapy as first line treatment for severe hypertension

Conditions: Hypertension

Summary: the purpose of this clinical research is to learn if severe hypertension can be better controlled by initially treating with a combination of drugs (irbesartan/hctz), in patients who are unlikely to achieve blood pressure (b/p) control with only one drug. in addition, the study will also evaluate the safety and tolerability of the drugs.


Eligibility criteria:
inclusion criteria: * men and women ages 18 and older; * willing to provide written informed consent; * must have uncontrolled hypertension defined as: currently untreated with a diastolic blood pressure greater than 110 mmhg or currently receiving antihypertensive monotherapy with a diastolic blood pressure greater than 100 mmhg. monotherapy is defined as treatment with one antihypertensive medication for at least four weeks; fixed combination therapy does not represent monotherapy; * must be willing to discontinue antihypertensive medication, if applicable; * women of childbearing potential (wocbp) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to one week after the study in such a manner that the risk of pregnancy is minimized. * wocbp must have a negative serum or urine pregnancy test within 72 hours prior to the start of study medication. exclusion criteria: * women who are pregnant or breastfeeding; * known or suspected secondary hypertension; * hypertension emergencies or stroke within the past 12 months; * heart attack, angina or bypass surgery within the past 6 months; * significant kidney disease; * significant liver disease; * systemic lupus erythematosus; * gastrointestinal disease or surgery that may interfere with drug absorption; * cancer during the past five years excluding localized squamous cell or basal cell carcinoma of the skin; * currently pregnant or lactating; * mental condition (psychiatric or organic cerebral disease) rendering the subject unable to understand the nature, scope, and possible consequences of the study; * drug or alcohol abuse within the last five years; * known allergy to irbesartan or diuretics.

Keywords: severe hypertension
augmenting urinary reflex activity: study 3

Conditions: Urinary Incontinence

Summary: aura-3 study (augmenting urinary reflex activity study 3) is a single arm, short-duration (8 month) cohort follow up study of preceding interventional medical device study, aura-2.


Eligibility criteria:
inclusion criteria: * participant has exited the aura-2 clinical investigation. * participant has an implanted amber ui system. * consents to participation. exclusion criteria: * participant has withdrawn from aura-2 clinical investigation. * participant is pregnant. * a past or current condition that in the opinion of the pi contraindicates enrolment (pi discretion).
dietary impact on urinary ph in women with interstitial cystitis

Conditions: Interstitial Cystitis

Summary: this is a pilot study on subjects who suffer from interstitial cystitis (ic) to assess the dietary affects on urine ph in relation to their symptoms. the goal of this pilot study is to determine which foods/beverages affect urinary ph and exacerbate patient's symptoms.

interstitial cystitis or painful bladder syndrome is a condition that is chronic and often debilitating in nature. interstitial cystitis is commonly defined by symptoms of urinary urgency and frequency associated with pelvic pain. around one million men and women in the united states and europe suffer from this condition. the diagnosis of interstitial cystitis is one of exclusion based on cystoscopy findings and clinical symptoms. common symptoms of interstitial cystitis include urinary frequency, urinary urgency, dysuria, and pain in the lower abdominal region, bladder, vagina, urethra, or in the perinea . women between ages 40 and 60 are the most commonly affect by interstitial cystitis. in the nurses' healthy study i and ii the prevalence of interstitial cystitis was 52-67 individuals out of 100,000. there is no single cause of interstitial cystitis however, there are several known theories to the cause of interstitial cystitis. a popular hypothesis is that a defect in the glycosaminoglycan layer of the bladder epithelium allows leakage and absorption of urinary solutes. the major solute that is responsible for causing bladder symptoms when the epithelium is injured is potassium. the long held notion is that patients with interstitial cystitis should avoid acidic foods. this logic is largely based on anecdotal data and questionnaires of foods, beverages and supplements that increase symptoms. controversy exists that interstitial cystitis diet restricts many more foods than necessary in an attempt to decrease interstitial cystitis symptoms. current questionnaires-based data suggest eliminating tomatoes, citrus fruits, vitamin c, artificial sweeteners, carbonated and alcoholic beverages, and spicy foods which are thought to exacerbate symptoms, while calcium glycerophosphate and sodium bicarbonate may improve symptoms. though the literature review, the investigators did not find any analytical studies that correlated diet with interstitial cystitis symptoms or that the ingestion of acidic foods exacerbate interstitial cystitis symptoms. based on the lack of analytical data and the impact of acidic food on ic symptoms this study is going to evaluate the potential renal acid load and net acid excretion of foods to determine which foods change urinary ph.

Eligibility criteria:
inclusion criteria: * women, diagnosed with interstitial cystitis or with a presumptive clinical diagnosis of ic * new ic patients who agree to hydrodistention and cystoscopy, the standard of care for diagnosis of ic exclusion criteria: * subjects who are diagnosed with fibromyalgia syndrome and subjects that are pregnant.